Boston Scientific has received FDA approval for Genesys HTA System for the treatment of menorrhagia. The system has also received CE mark approval in January.
Boston Scientific claimed that Genesys HTA System is an endometrial ablation system designed to ablate the endometrial lining of the uterus in premenopausal women with menorrhagia.
Boston Scientific said that Genesys HTA System represents an advance in its endometrial ablation technology. It features a smaller and lighter console, simplified set-up requirements, and an enhanced graphic user interface which offers step-by-step guidance through the procedure.
The Genesys HTA System also incorporates several technology upgrades designed to improve operating performance while delivering the same proven clinical therapy of the company’s current HTA Endometrial Ablation System.
John Pedersen, senior vice president and president of urology and women’s health division at Boston Scientific, said: “FDA approval of the Genesys HTA System is the latest example of our commitment to developing products in the Women’s Health arena that improve patients’ lives. We are pleased we will be able to offer this next-generation system to US patients suffering from menorrhagia.”